Evidence map›Paper›PMID 34221275›Full record

ArticleCaspian journal of internal medicine2021

Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study.

Rozita Doosti, Abdorreza Naser Moghadasi, Amir Reza Azimi, Shahrokh Karbalai Saleh, Masoud Etemadifar, Vahid Shaygannejad, Fereshteh Ashtari, Mohammad Hossein Harirchian, Seyed Bahaadin Siroos, Hormoz Ayramloo and 14 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Caspian journal of internal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 10 institutions in 1 country.

Rozita DoostiMultiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
Abdorreza Naser MoghadasiMultiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
Amir Reza AzimiMultiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
Shahrokh Karbalai SalehDepartment of Cardiology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Masoud EtemadifarDepartment of Functional Neurosurgery, Medical School, Isfahan University of Medical Sciences, Isfahan, Iran.
Vahid ShaygannejadIsfahan Neuroscience Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Fereshteh AshtariIsfahan Neuroscience Research Center, Isfahan University of Medical Sciences, Kashani MS center, Isfahan, Iran.
Mohammad Hossein HarirchianIranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Imam Khomeini Hospital, Tehran, Iran.
Seyed Bahaadin SiroosIranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Imam Khomeini Hospital, Tehran, Iran.
Hormoz AyramlooDepartment of Neurology, Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.
Nastaran MajdinasabDepartment of Neurology, Golestan Hospital, Ahwaz University of Medical Sciences, Iran.
Seyyed Mohammad Masood HojjatiDepartment of Neurology, Babol University of Medical Sciences, Babol, Iran.
Nabiollah AsghariFaculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran.
Seyed Mohammad BaghbanianDepartment of Neurology, Booalisina Hospital, Mazandaran University of Medical Sciences, Sari, Iran.
Hamed CheraghmakaniDepartment of Neurology, Booalisina Hospital, Mazandaran University of Medical Sciences, Sari, Iran.
Mahmoud AbediniDepartment of Neurology, Mazandaran University of Medical Sciences, Sari, Iran.
Behnaz SedighiNeurology Research Center, Kerman University of Medical Science, Kerman, Iran.
Negar Mohseni Abbas AbadiR&D Department, Osve Pharmaceutical Co., Tehran, Iran.
Maedeh GhasemitabarR&D Department, Osve Pharmaceutical Co., Tehran, Iran.
Sara TalebianpourR&D Department, Osve Pharmaceutical Co., Tehran, Iran.
Tohid Babayi DaylariR&D Department, Osve Pharmaceutical Co., Tehran, Iran.
Vahid DanaR&D Department, Osve Pharmaceutical Co., Tehran, Iran.
Neda Ghaleh NoieQuality Assurance Department, Osve Pharmaceutical Co., Tehran, Iran.
Mohammad Ali SahraianMultiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
Tehran University of Medical Sciences · IRMazandaran University of Medical Sciences · IRImam Khomeini Hospital · IRIsfahan University of Medical Sciences · IRBabol University of Medical Sciences · IRGolestan University · IRKerman University of Medical Sciences · IRSemnan University of Medical Sciences · IRSina Hospital · IRTabriz University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFingolimod was the first oral therapy approved for treating relapsing-remitting multiple sclerosis (RRMS) in 2010. This open-label study evaluated the safety and efficacy of fingolide

methodsA multicenter, open-label, longitudinal was designed to evaluate the safety and efficacy of fingolide

resultsA total of 252 patients with the mean treatment duration of 343±45.70 days were. 20 patients experienced adverse events (AEs) and serious adverse events (SAEs) such as resistant urinary tract infection (UTI), premature atrial contraction (PAC), skin allergic reaction, macular edema, chicken pox, zona, panic attacks, and exacerbations associated with steroids treatment, all of which led to Fingolide

conclusionThe obtained findings suggest that the administration of Fingolide

Indexed as

EDSSEfficacyFingolimodMultiple SclerosisSafety

Identifiers

PMID34221275
PMCPMC8223042
OpenAlexW3169941265

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.